Curaderm BEC5 for Skin Cancers, Is It? An Overview

@article{Chase2011CuradermBF,
  title={Curaderm BEC5 for Skin Cancers, Is It? An Overview},
  author={Tania Robyn Chase},
  journal={Journal of Cancer Therapy},
  year={2011},
  volume={2011},
  pages={728-745}
}
  • T. Chase
  • Published 31 December 2011
  • Biology
  • Journal of Cancer Therapy
Skin cancer incidence is increasing at alarming rates and is considered by some as an epidemic. Its incidence is higher than all other cancers combined. The developments of new treatments have not parallelled the increased incidences of this disease. A variety of treatments are available with differing outcomes. More recently a novel topical treatment, consisting of the antineoplastic compounds solasodine rhamnosyl glycosides, solamargine and solasonine, which are derived from plant material… 
Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes
TLDR
It is shown that CuradermBEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.
Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies
TLDR
An overview of the overwhelming resurgence of solasodine and its glycosides in cancer therapy is given and the need for improved cancer therapies is self-evident.
A review of solasodine rhamnosides therapy for in-situ squamous cell carcinoma on the penis.
TLDR
Three cases of distinct squamous cell carcinomas on the penis, Bowen’s disease, erythroplasia of Queyrat and Buschke-Lowenstein tumour are reviewed which were successfully treated with a standard mixture of solasodine rhamnosides.
Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities
Dermatologists, surgeons, oncologists and radiotherapists usually jointly manage skin cancers. The strengths and limitations of the established procedures are known. A new naturally derived topical
Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma
TLDR
Curaderm pharmacotherapy effectively and safely treats virtually all types, sizes and lesion locations and covers the discovery of the anti-cancer effects, mode of action, preclinical, clinical and field applications with emphasis on efficacy, safety, compliance, tolerance, cost effectiveness and especially cosmetic outcome.
Intralesion and curaderm BEC5 topical combination therapies of solasodine rhamnosyl glycosides derived from the eggplant or Devil’s apple result in rapid removal of large skin cancers. methods of treatment compared
TLDR
It is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime.
Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents
TLDR
This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.
Squamous Cell Carcinoma (SCC) and Chronic Radiation Dermatitis Associated with Childhood Ionizing Radiation Exposure: Case Report with Review of the Literature
TLDR
Patients with a history of repeated IR exposure, particularly from older, unregulated sources such as a shoe-fitting fluoroscope, should be monitored with a high index of suspicion for skin cancer and other related problems.
Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with Curaderm BEC5
TLDR
The efficacy and safety of a topical cream therapy, CuradermBEC5, containing solasodine glycosides (0.005%) for actinic keratosis, and its effectiveness and safety are described are described.
A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
TLDR
It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports
TLDR
Two cases are reported which show that BEC in a cream formulation Curaderm is very effective for the treatment of large nonmelanoma skin cancers that are considered difficult to treat by existing modalities.
Intralesion and curaderm BEC5 topical combination therapies of solasodine rhamnosyl glycosides derived from the eggplant or Devil’s apple result in rapid removal of large skin cancers. methods of treatment compared
TLDR
It is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime.
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
During the past several decades, there has been a substantial increase in the incidence of cutaneous melanoma among all caucasian populations. The number of deaths due to cutaneous malignant melanoma
Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin.
Solasodine rhamnosyl glycosides cause apoptosis in cancer cells. Do they also prime the immune system resulting in long-term protection against cancer?
TLDR
Data is presented that in addition to apoptosis and, perhaps as a consequence thereof, SRGs also have an effect of stimulating lasting immunity against cancer as shown with a mouse model and the terminal cancer Sarcoma 180.
Incompletely excised basal cell carcinoma: a management dilemma?
TLDR
Observation is an acceptable management option in most situations, as only one-third of incompletely excised lesions needed further treatment.
...
...